CS
RYTM icon

Credit Suisse’s Rhythm Pharmaceuticals RYTM Stock Holding History

Credit Suisse’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$1.87M Buy
43,164
+1,152
+3% +$50.4K ﹤0.01% 1901
2023
Q4 		$1.93M Sell
42,012
-1,306
-3% -$41.2K ﹤0.01% 1908
2023
Q3 		$993K Sell
43,318
-25,683
-37% -$575K ﹤0.01% 2310
2023
Q2 		$1.14M Buy
69,001
+13,710
+25% +$247K ﹤0.01% 2296
2023
Q1 		$986K Buy
55,291
+7,879
+17% +$198K ﹤0.01% 2339
2022
Q4 		$1.38M Buy
47,412
+11,928
+34% +$307K ﹤0.01% 2118
2022
Q3 		$869K Buy
35,484
+10,962
+45% +$204K ﹤0.01% 2431
2022
Q2 		$102K Sell
24,522
-2,749
-10% -$15K ﹤0.01% 3524
2022
Q1 		$314K Sell
27,271
-1,146
-4% -$10.1K ﹤0.01% 3203
2021
Q4 		$283K Buy
28,417
+2,837
+11% +$31.9K ﹤0.01% 4141
2021
Q3 		$335K Buy
25,580
+1,778
+7% +$27.2K ﹤0.01% 4043
2021
Q2 		$467K Sell
23,802
-1,654
-6% -$34.3K ﹤0.01% 3887
2021
Q1 		$541K Sell
25,456
-18,820
-43% -$546K ﹤0.01% 3716
2020
Q4 		$1.32M Buy
44,276
+27,216
+160% +$692K ﹤0.01% 3128
2020
Q3 		$369K Sell
17,060
-19,993
-54% -$458K ﹤0.01% 3539
2020
Q2 		$826K Buy
37,053
+22,915
+162% +$447K ﹤0.01% 3009
2020
Q1 		$215K Sell
14,138
-1,014
-7% -$18.2K ﹤0.01% 3611
2019
Q4 		$347K Buy
15,152
+3,846
+34% +$85.4K ﹤0.01% 3758
2019
Q3 		$244K Sell
11,306
-2,877
-20% -$61.7K ﹤0.01% 3793
2019
Q2 		$311K Buy
14,183
+4,648
+49% +$117K ﹤0.01% 3663
2019
Q1 		$261K Buy
9,535
+855
+10% +$24.6K ﹤0.01% 3658
2018
Q4 		$233K Sell
8,680
-7,270
-46% -$201K ﹤0.01% 3616
2018
Q3 		$466K Buy
15,950
+7,154
+81% +$226K ﹤0.01% 3346
2018
Q2 		$275K Buy
+8,796
New +$241K ﹤0.01% 3655

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Credit Suisse's RYTM Position: Q1 2024 in Review

Credit Suisse increased its Rhythm Pharmaceuticals (RYTM) stake by 2.7% in Q1 2024, buying an estimated $50.4K and bringing the position to 43,164 shares worth $1.87M. The position accounts for ﹤0.01% of the portfolio, ranked #1901.

Credit Suisse first reported a position in RYTM in Q2 2018 and has held it in 24 quarters since. The position peaked at $1.93M in Q4 2023. 167 funds tracked by Wall St. Rank hold RYTM as of Q1 2024.

  • Credit Suisse held 43,164 shares of Rhythm Pharmaceuticals worth $1.87M as of Q1 2024.
  • Credit Suisse bought 1,152 Rhythm Pharmaceuticals shares in Q1 2024, an estimated $50.4K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1901 holding.
  • Credit Suisse first reported a position in Rhythm Pharmaceuticals in Q2 2018 and has held it in 24 quarters since.
  • Credit Suisse's Rhythm Pharmaceuticals position peaked at $1.93M in Q4 2023.
  • 167 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.